Orthobiologics

FDA approved an expansion to its Phase I/II clinical program to include three spinal fusion indications and tripling the number...

Three of the company’s MagnetOs bone graft formulations are already indicated for use beyond spine procedures....

LDGraft is a combination product that delivers recombinant human bone morphogenetic protein-2 through a biodegradable polymer....

The FDA clearance allows NovaBone Putty to be used in the intervertebral disc space alongside FDA-cleared interbody fusion devices....

CITREPORE is a synthetic bioactive bone void filler composed of patented CITREGEN biomaterial technology....

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards,...

The designation covers use of a drug/device combination product to treat degenerative disc disease with transforaminal lumbar interbody fusion....

Results support integration of antibiotic-eluting bone substitute materials, like CERAMENT G and CERAMENT V, into treatment guidelines for orthopedic infections....

i-FACTOR is now approved for single-level ACDF with an allograft bone ring, or with a PEEK, titanium alloy or PEEK/titanium...

The trial is evaluating SB-01, the first intradiscal pharmacologic treatment to enter Phase III studies for the treatment of chronic...